Etoposide

For research use only. Not for use in humans.

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 17100 あり
JPY 13600 あり
JPY 48400 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(121)

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M1XBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqwTWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= NHK1[HQzPTl4MEK4Ni=>
KellyCis83 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXETWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= NEnLOZIzPTl4MEK4Ni=>
SK-N-AS NXy1e5pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37BNmlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= NYTlSnNGOjV7NkCyPFI>
SK-N-ASCis24 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnmSm5QUUN3ME2wMlU46oDLwsJihKkxNjFzIN88US=> MYKyOVk3ODJ6Mh?=
U87 NH2ySldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGwMVUxKM7:TR?= MYG0PEBp MmDC[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? MV[yOVc2ODJ5Mx?=
HCT116 NX[2[IxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD2cXQxNjVvMj61JO69VQ>? MkXUOFjDqGkEoB?= NEPiRnJKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= NXTvVJJbOjV5NE[3OlM>
HT-29 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDSRXJbOC53LUKuOUDPxE1? Mn7ROFjDqGkEoB?= MX3JR|UxRTdwMtMgxtHDqDFwMEVCpO69VQ>? MoTSNlU4PDZ5NkO=
Caco2 M3\ISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWwMlUuOi53IN88US=> NW\XeVRYPDkEoHlCpC=> NH\tbFNKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= MVuyOVc1Pjd4Mx?=
COLO 205 M3;5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv4N|dJOC53LUKuOUDPxE1? MkXYOFjDqGkEoB?= Mny5TWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP NVjFSm15OjV5NE[3OlM>
SW480 NFHpXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrZNE42NTJwNTFOwG0> NWDUOIh{PDkEoHlCpC=> MWfJR|UxRTRwOUNCpOKyyqByLkOzxsDPxE1? M2rJR|I2PzR4N{[z
HEK293T MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[xMVUh|ryP NYr4dW1QPDkEoHlCpC=> NFfxcoZKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= NF\sUpMzPTd2Nke2Ny=>
Hep3B  NUnhUmx{TnWwY4Tpc44hSXO|YYm= NF3ZfWgyOCEQvF2= NHvGXnI1QMLiaNMg M3jkeZJm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> NXriO5lzOjV4M{O1OlQ>
Hep3B  MmP6SpVv[3Srb36gRZN{[Xl? M1vKXlAvOS1zMDFOwG0> NGrGNWIzPCCq NUXoWVN2e3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B MoG3NlU3OzN3NkS=
HEK293 NWPtO|lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fKdWlEPTB;Nz6xOOKhyrIEoECuN|bDqM7:TR?= M1qxW|I2PjB|MUKy
DU145 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwMklCpOKyyqByLkC0xsDPxE1? NV;yO2ViOjV4MEOxNlI>
HCT15 NUTGVWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX4bY1KSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= MUeyOVYxOzF{Mh?=
T47D NGfF[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvSTWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP MUKyOVYxOzF{Mh?=
SMMC-7721 NIT3SVFHfW6ldHnvckBCe3OjeR?= MWW0NEDPxE1? NWr1S4Y3PDhiaB?= MYDEUXNQ NI\RVlJqdmS3Y3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdg>? MmHJNlU2PDR|NkG=
MDA-MB-231 M1TEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NuKhcA>? MnTGTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? NFPCcWMzPTR6NkKxPS=>
MCF-7 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVm3NuKhcA>? M2TqWGlEPTB;MUCuPeKhyrIEoEKuNeKh|ryP MkfhNlU1QDZ{MUm=
Jurkat NGXEO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7mRpQ4OsLiaB?= NEPZbWFKSzVyPUGuNuKhyrIEoEGuOeKh|ryP NGfKVGkzPTR6NkKxPS=>
HeLa MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;rcVczyqCq MWnJR|UxRTNwOdMgxtHDqDJwM9Mg{txO MnzONlU1QDZ{MUm=
MCF7  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DuOlUuOTByIN88US=> NYPobGdGPyCm NXvEXGJNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIPm[nUzPTR5Mk[xPS=>
K562 NV\jRWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS5e2ZvPzMEoHi= NHPocVdKSzVyPUCuNlnDqM7:TR?= Mn7yNlUzQDJ4NUO=
K/VP.5 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLOXGJvPzMEoHi= M3TV[GlEPTB;ND65xsDPxE1? MV6yOVI5OjZ3Mx?=
SH-EP  M2rlW2Z2dmO2aX;uJGF{e2G7 MVGyNOKh|rypL33s NH;MRlkzPMLiaB?= M2K4W4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= MX2yOVI3OTl6MR?=
SCC25 NEjDWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\yXIkzPMLiaB?= NW[5UJlRUUN3ME20N{4{yqEEsdMgNU4yOsLizszN MV:yOVIzODd{OR?=
CAL27 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\3ZlI1yqCq NX:3SZFbUUN3ME21Nk4yyqEEsdMgNU4xQcLizszN M{O0NlI2OjJyN{K5
FaDu MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7PUZN6OjUEoHi= MmfNTWM2OD1{NT64PeKhyrIEoEGuNVPDqM7:TR?= M3W0Z|I2OjJyN{K5
SCC25 NU[2VXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[xR3NUPDkEoHi= M4Pmc2lEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= NETWeokzPTJ{MEeyPS=>
CAL27 NXT3S2huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXi0POKhcA>? MmW1TWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= M3vQSVI2OjJyN{K5
FaDu NFTkO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S2NVQ5yqCq MX3JR|UxRTZwNERCpOKyyqBzLkGzxsDPxE1? NX2xU5o5OjV{MkC3Nlk>
SCC25 M3rmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjBO|LDqGh? NIjifHFKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= M2Dre|I2OjJyN{K5
CAL27 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzNUmo4OsLiaB?= MoXBTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP M{HaSVI2OjJyN{K5
FaDu M4\R[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu4XFQ4OsLiaB?= MXHJR|UxRTVwMENCpOKyyqBzLkG1xsDPxE1? MnnyNlUzOjB5Mkm=
MCF-7 M{LmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXS0POKhcMLi NXraWJZuTE2VTx?= M4fjUWlEPTB;Nz6yxsDDucLiMD64xsDPxE1? MVSyOVIyPjN5OB?=
T-47D NF7VW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFflV4Q1QMLiaNMg Mn7SSG1UVw>? M4XC[GlEPTB;Nz63xsDDucLiMD63xsDPxE1? MV:yOVIyPjN5OB?=
MDA-MB-231 M3vDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vCclQ5yqCqwrC= NV73bWh3TE2VTx?= MUHJR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? NV7KbGxDOjV{MU[zO|g>
DU145 NUnlRWlsSXCxcITvd4l{KEG|c3H5 MV:xNE0yODBizszN NIX4VGk5KGh? MVXEUXNQ MnnabY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w NIDzR2IzPTF2OU[4NS=>
DU145 stem-like NYDNfVRxSXCxcITvd4l{KEG|c3H5 MorkNVAuOTByIN88US=> Mkn4PEBp M4XiR2ROW09? NFXISJBqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3;OO|I2OTR7Nkix
DU145 M3PY[WZ2dmO2aX;uJGF{e2G7 NHvx[HcyOC1zMECg{txO M{mxOlIhcA>? Mo\2SG1UVw>? NIPPZ2NqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVyyOVE1QTZ6MR?=
DU145 stem-like NWrMUIpSTnWwY4Tpc44hSXO|YYm= NFzVUYIyOC1zMECg{txO M4PoO|IhcA>? MmLQSG1UVw>? M2fq[Ylv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIDaRZkzPTF2OU[4NS=>
UW228-3 M3\2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOwMlAyNTNyMDFOwG0> M{[0NFQ5KGh? NYXIOHBUTE2VTx?= NGC2O25KSzVyPUCuPVnDqM7:TR?= MXGyOVEyQTF6NR?=
NSCs MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfiNE4xOS1|MECg{txO NWPrfGF[PDhiaB?= NF:wUGtFVVOR NELON5NKSzVyPUCuN{0{yqEQvF2= NGf6dWczPTFzOUG4OS=>
MKL-1  Mm\ySpVv[3Srb36gRZN{[Xl? NXvRV|N{OTBvMUCwNEBvVQ>? MUK0JIQ> M3PmXIlv\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDNTGMuUSCneIDy[ZN{cW:w NET6eXYzPTFzNke1OC=>
MCF7 EV MkXESpVv[3Srb36gRZN{[Xl? MlPDNVAuOTByIN88US=> M2P5UVLjiImq NXmzVXR2cW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? M2rTdlI2ODh6MkCz
MCF 7BMI1 MnrESpVv[3Srb36gRZN{[Xl? NEDQSYQyOC1zMECg{txO M4rIe|LjiImq NXrzZmZ3cW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? MWKyOVA5QDJyMx?=
MCF7 EV MmXhSpVv[3Srb36gRZN{[Xl? MlTWNVAuOTByIN88US=> NG[5dpkz6oDLaB?= MkX0SXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u NFzS[Y0zPTB6OEKwNy=>
MCF7 BMI1 MoG5SpVv[3Srb36gRZN{[Xl? NYLSSo55OTBvMUCwJO69VQ>? MmSzNwKBkWh? MU\FWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= NWftU4k1OjVyOEiyNFM>
HepG2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnEUXNQyqB? NH;FS3RKSzVyPUOwMlE3yqEEsdMgNE42OMLizszN M3PISFI2ODd6M{Gx
MOLT-3 NXuyPFVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XXZmROW00EoB?= NGHuNGhKSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> NE\TWXAzPTB5OEOxNS=>
HT1080 NULHV2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz4NU0yODBizszN NYHRU|dJPC9{ND:0PEBp MWDEUXNQyqB? NXT4T3F3cW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u M4TIT|I2ODd6ME[0
HT1080 MmHkSpVv[3Srb36gRZN{[Xl? M{PEfFAvODByMT2xNFAh|ryP MoT1NU0zPCCq NEXwfHZFVVORwrC= NVnBSXJJcW6mdXPld{BxNXB3Mzjz[ZIyPSliaX6gZo91cCC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy NIfYNo0zPTB5OEC2OC=>
HT1080 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHXXJMxNjByMEGtNVAxKM7:TR?= M4T4W|I1KGh? NFLkc5ZFVVORwrC= NIr4bnZk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz MoPmNlUxPzhyNkS=
HD-MY-Z M1LP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHmwPVMzPC92OD:3NkBp Ml20TWM2OO,:nkGwNEDPxE1? MnX2NlUxPDh{M{[=
DOHH-2 M{jjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGyOEBp MX;JR|Ux97zgMUCwJO69VQ>? MkTFNlUxPDh{M{[=
DOHH-2 M3O5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHXOFghcA>? M2\5d2lEPTB;MUmuPeKh|ryP MnLHNlUxPDh{M{[=
DOHH-2 M3TNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;EO|IhcA>? M2q2dWlEPTB;NdMg{txO M1zNV|I2ODR6MkO2
REH NFzaWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknhNlQhcA>? M3W2UWlEPTB;MD6wNlfDqM7:TR?= NVjuSIVTOjVyNEiyN|Y>
REH MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHPVIhnPDhiaB?= NWLn[Wg5UUN3ME2wMlAyPMLizszN MXqyOVA1QDJ|Nh?=
REH MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33odFczKGh? M4XNOGlEPTB;MD6wNVXDqM7:TR?= MoLtNlUxPDh{M{[=
HH NXjm[pJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[yOEBp NXH6NlFSUUN3ME2xNFQvP8LizszN M2P5T|I2ODR6MkO2
HH M1XNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTGOFghcA>? MonITWM2OD12OD62xsDPxE1? Mly0NlUxPDh{M{[=
HH M1PXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnEeoFIPzJiaB?= M4rub2lEPTB;MUSuO:Kh|ryP M1jPTFI2ODR6MkO2
HuT-78 NH\YOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDmNlQhcA>? NEHLRnRKSzVyPUmuN:Kh|ryP NXzteWo5OjVyNEiyN|Y>
HuT-78 NI\uV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq0PEBp NYfGcoJpUUN3ME20MlPDqM7:TR?= NVnHVHdKOjVyNEiyN|Y>
HuT-78 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi3NkBp M4e3WmlEPTB;ND6yxsDPxE1? NEDnNYczPTB2OEKzOi=>
OPM-2 NXLMV4lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nQc|I1KGh? MUDJR|UxRTJ2LkJCpO69VQ>? NWmyOnhKOjVyNEiyN|Y>
OPM-2 NUW2PZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LO[FQ5KGh? Mlf1TWM2OD12wrFOwG0> MXKyOVA1QDJ|Nh?=
OPM-2 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LvSFczKGh? NFzYOHZKSzVyPUGuN:Kh|ryP NGLsWGEzPTB2OEKzOi=>
RPMI-8226 M2DqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uwWlI1KGh? NYjOU5hpUUN3ME2xNFYvPsLizszN MXOyOVA1QDJ|Nh?=
RPMI-8226 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojBOFghcA>? MYTJR|UxRTlzLkJCpO69VQ>? NIryUpczPTB2OEKzOi=>
RPMI-8226 NF\PNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLFO|IhcA>? M{XoOWlEPTB;MUSuPeKh|ryP NVXwR4JpOjVyNEiyN|Y>
U-266 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnOe|gzPCCq NIHiNZRKSzVyPUi2MlLDqM7:TR?= MlX3NlUxPDh{M{[=
U-266 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqw[GM1QCCq NHLEcXRKSzVyPU[4MlTDqM7:TR?= MlfPNlUxPDh{M{[=
U-266 NHToV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXaW2x{PzJiaB?= M3XzWWlEPTB;MkeuOOKh|ryP MViyOVA1QDJ|Nh?=
Kelly M2m0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGwMVExKM7:TR?= MXS3NuKhcA>? M{jReWlEPTB;MT61NVjDqM7:TR?= MVWyOVAxQDlyMB?=
SH-SY5Y  NWnTVm9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGwMVExKM7:TR?= MVm3NuKhcA>? NX[3W3FZUUN3ME2wMlc2PMLizszNxsA> M4C0cVI2ODB6OUCw
SK-N-AS M1S0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe3cowxNTFyIN88US=> MnvkO|LDqGh? M1\TOGlEPTB;MT63NVLDqM7:TdMg NGXtcZYzPTByOEmwNC=>
SK-N-DZ NGfmdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjaNGM{OC1zMDFOwG0> NV;XZnBGPzMEoHi= MVHJR|UxRTVwNEi1xsDPxE1? MUWyOVAxQDlyMB?=
HepG2 NHXle2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\2OFjDqGh? MYXEUXNQyqB? M1rOU2lEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= NF\QUGIzPDl7NkGzOi=>
A549 M1zqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV60POKhcA>? Ml\rSG1UV8Li MV;JR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= M{HwNFI1QTl4MUO2
MCF7 NVXIN3BoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:0POKhcA>? MWXEUXNQyqB? M3zqT2lEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN M4LUNFI1QTl4MUO2
HL-60  MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq2O|LDqGh? MYnJR|UxRTBwMUNihKXPxE1? M4fpXFI1QTl|MEG0
HL-60[R] M{TvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ZN4t{PzMEoHi= MnL6TWM2OD1|LkGy5qCG|ryP M2\reVI1QTl|MEG0
MIAPACA M3;VO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDzS2k2OD1zLkOgxtEhOC5yMzFOwG0> MUiyOFk2Ozh{MR?=
MCF-7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rRU2dKPTB;MD6yOUDDuSByLkGg{txO NGHZUIwzPDl3M{iyNS=>
HeLa M4\lUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLHTVUxRTBwNkSgxtEhOC52IN88US=> MWqyOFk2Ozh{MR?=
MO59K  Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fkclch\A>? NULwV2I6UUN3ME2wMlE46oDHzszN MkLtNlQ6PTN3NkG=
MO59J MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW1O{Bl M1e2SWlEPTB;MD6x5qCG|ryP MoHiNlQ6PTN3NkG=
ME 180 NHT1fG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LzSVQ5yqCqwrC= M{DjTGlEPTB;OD65xsDDucLiMD6z5qCG|ryP NYHuXYR2OjR7NUOwNlc>
MCF-7 M4r3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[0POKhcMLi MkT6TWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? NHPXdHAzPDl3M{CyOy=>
HeLa NHHTSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe0POKhcMLi M1vKb2lEPTB;ND63NUDDuSBzLkVihKXPxE1? MnHyNlQ6PTNyMke=
MDA-MB-453 Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGxVYM1QMLiaNMg MonTTWM2OD1zMj61JOKyKDBwOEZihKXPxE1? MUGyOFk2OzB{Nx?=
MDA-MB-231 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjTbWQ4PDkEoHlCpC=> MkLTTWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP MWiyOFk2OzB{Nx?=
PC-3 NYLmWXQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO0POKhcMLi MlvCTWM2OD1zND60JOKyKDNwMkRihKXPxE1? M37oVlI1QTV|MEK3
HT-29 NHzKVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nZclQ5yqCqwrC= MVHJR|UxRTJzLkS1JOKyKDNwOEhihKXPxE1? NETFW5gzPDl3M{CyOy=>
BGC-823 M{mxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIezb4E1QMLiaNMg M2PPe2lEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= MVeyOFc6Ozh5Nx?=
HeLa Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3GRYp4PDkEoHlCpC=> NXXObVgzUUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO M33OcVI1Pzl|OEe3
A549 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWToZWN2PDkEoHlCpC=> NILvU5BKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN MUSyOFc6Ozh5Nx?=
HK-2 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXq0POKhcMLi M{LBN2lEPTB;OT6xO{DDuSBzLkW45qCG|ryP NEHzXmUzPDd7M{i3Oy=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
- 合併

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
- 合併
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
- 合併
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
15mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
in solvent
別名 VP-16, VP-16213
Smiles COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(OC4OC5COC(C)OC5C(O)C4O)C6=C2C=C7OCOC7=C6

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03264131 Recruiting Drug: Brentuximab Vedotin|Drug: CHEP Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. October 15 2018 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID